Stock ANGO ANGIODYNAMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
6.17 USD +0.82% Intraday chart for AngioDynamics, Inc. -3.89% -21.30%
May. 21 AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System MT
May. 06 AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV) CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System
AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate
AngioDynamics Sells Two Product Lines to Spectrum Vascular for up to $45 Million Cash; Shares Up in Pre-Bell Trading
Spectrum Vascular acquired PICC and Midline Product Portfolios from AngioDynamics, Inc. for $45 million.
Angiodynamics, Inc. Announces Board Changes
AngioDynamics Receives FDA Clearance for Auryon XL Radial Access Catheter
Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease
AngioDynamics, Inc. Announces Dennis Meteny to Retire as A Member of the Board of Directors, Member of the Compensation Committee and Chair of the Audit Committee, Effective January 31, 2024
Sector Update: Health Care Stocks Retreat Late Afternoon
AngioDynamics Shares Fall After Q2 Swing to Adjusted Loss; Revenue Drops
Top MIdday Decliners
AngioDynamics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023
David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024
AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2024
AngioDynamics Completes Patient Enrollment in Device Trial for Pulmonary Embolism Treatment
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANGO Stock
  4. News AngioDynamics, Inc.
  5. Other languages